Systemic sclerosis and malignancy: A review of the literature

Southern Medical Journal

Volumn 101, Issue 1, 2008, Pages 59-62

  Wooten, Marc ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cancer; Cohort; Malignancy; Scleroderma; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; DNA TOPOISOMERASE;

AGE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DISEASE COURSE; GENDER; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; INCIDENCE; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; PREVALENCE; REVIEW; SYSTEMIC SCLEROSIS; UROGENITAL TRACT CANCER; UROGENITAL TRACT DISEASE;

BREAST NEOPLASMS; COMORBIDITY; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASMS; RISK FACTORS; SCLERODERMA, SYSTEMIC; SEX FACTORS; TIME FACTORS;

EID: 37849038703     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31815838ce     Document Type: Review

References (44)

1. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-2255.
2. Allcock RJ, Forrest I, Corris PA, et al. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology 2004;43:596-602.
3. Duncan SC, Winkelmann RK. Cancer and scleroderma. Arch Dermatol 1979;115:950-955.
4. Hill CL, Nguyen AM, Roder D, et al. Risk of cancer in patients with scleroderma: a population-based cohort study. Ann Rheum Dis 2003;62:728-731.
5. Roumm AD, Medsger TA. Cancer and systemic sclerosis: an epidemiological study. Arthritis Rheum 1985;28:1336-1340.
6. Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheum 1993;36:460-464.
7. Rosenthal AK, McLaughlin JK, Gridley G, et al. Incidence of cancer among patients with systemic sclerosis. Cancer 1995;76:910-914.
8. Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005;52:2415-2424.
9. Derk CT, Rasheed M, Artlett CM, Jiminez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006;33:1113-1116.
10. Sakauchi F, Mori M, Ishikawa O, Endo H. [The association of systemic sclerosis with malignant neoplasms.] Nihon Rinsho Meneki Gakkai Kaishi 2004;27:402-406.
11. Derk CT, Arnett CM, Jimenez SA. Morbidity and mortality of patients diagnosed with systemic sclerosis after the age of 75: a nested casecontrol study. Clin Rheumatol 2006;25:831-834.
12. Ardern-Jones MR, Black MM. Widespread morphoea following radiotherapy for carcinoma of the breast. Clin Exp Dermatol 2003;28:160-162.
13. Bleasel NR, Stapleton KM, Commens C, et al. Radiation-induced scleroderma in breast cancer patients. Australas J Dermatol 1999;40:99-102.
14. Davis DA, Cohen PR, McNeese MD, et al. Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: radiation port scleroderma. J Am Acad Dermatol 1996;35:923-927.
15. Wenzel J. Scleroderma and malignancy: mechanisms of interrelationship. Eur J Dermatol 2002;12:296-300.
16. Asano Y, Ihn H, Shikada J, et al. A case of peplomycin-induced scleroderma. Br J Dermatol 2004;150:1213-1214.
17. Battafarano DF, Zimmerman GC, Older SA, et al. Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases. Cancer 1995;76:110-115.
18. De Angelis R, Bugatti L, Cerioni A, et al. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. Clin Rheumatol 2003;22:49-52.
19. Farrant PB, Mortimer PS, Gore M. Scleroderma and the taxanes: is three really a link? Clin Exp Dermatol 2004;29:360-362.
20. Hassett G, Harnett P, Manolios N. Scleroderma in association with the use of docetaxel (taxotere) for breast cancer. Clin Exp Rheumatol 2001;19:197-200.
21. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998;57:682-686.
22. Villa AR, Kraus A, Jimenez-Corona A, et al. Malignant neoplasms in autoimmune rheumatic diseases: examination of the risk of developing a malignancy among five different rheumatic diseases in one institution. J Clin Rheumatol 2000;6:176-183.
23. Sakkas LI, Moore DI, Akritidis NC. Cancer in families with systemic sclerosis. Am J Med Sci 1995;310:223-225.
24. Roberts-Thomson PJ, Male DA, Walker JG, et al. Genomic instability in scleroderma. Asian Pac J Allergy Immunol 2004;22:153-158.
25. Kuwana M, Okasaki Y, Yasouka H, et al. Defective vasculogenesis in systemic sclerosis. Lancet 2004;364:603-610.
26. Meyer O. Prognostic markers for systemic sclerosis. Joint Bone Spine 2006;73:490-494.
27. Yang Y, Fujita J, Tokuda M, et al. Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int 2001;21:106-111.
28. Daniels CE, Jett JR. Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med 2005;11:431-437.
29. Peters-Golden M, Wise RA, Hochberg M, et al. Incidence of lung cancer in systemic sclerosis. J Rheumatol 1985;12:1136-1139.
30. Talbott JH, Barrocas M. Carcinoma of the lung in progressive systemic sclerosis: a tabular review of the literature and a detailed report of the roentgenographic changes in two cases. Semin Arthritis Rheum 1980;9:191-217.
31. Kanaji N, Fujita J, Bandoh S, et al. Small cell lung cancer associated with systemic sclerosis. Intern Med 2005;44:315-318.
32. Forbes AM, Woodrow JC, Verbov JL, et al. Carcinoma of breast and scleroderma: four further cases and a literature review. Br J Rheumatol 1989;28:65-69.
33. Launay D, Le Berre R, Hatron PY, et al. Association between systemic sclerosis and breast cancer: eight new cases and review of the literature. Clin Rheumatol 2004;23:516-522.
34. Scope A, Sadetzki S, Sidi Y, Barzilai A, et al. Breast cancer and scleroderma. Skin Med 2006;5:18-24.
35. Halpert RD, Laufer I, Thompson JJ, et al. Adenocarcinoma of the esophagus in patients with scleroderma. Am J Roentgenol 1983;140:927-930.
36. Katzka DA, Reynolds JC, Saul SH, et al. Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma. Am J Med 1987;82:46-52.
37. Wipff J, Allanore Y, Soussi F, et al. Prevalence of Barrett's esophagus in systemic sclerosis. Arthritis Rheum 2005;52:2882-2888.
38. Boyeldieu D, Rouquette-Gally AM, Laugler A, et al. [Anticentromere antibody, CREST, and cancer.] Presse Med 1987;16:1924-1925.
39. Higuchi M, Horiuchi T, Ishibashi N, et al. Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis. Clin Rheumatol 2000;19:123-126.
40. Weiner ES, Earnshaw WC, Senecal JL, et al. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I: a study of 355 patients. Arthritis Rheum 1988;31:378-385.
41. Rothfield N, Kurtzman S, Vazgues-Abad D, et al. Association of antitopoisomerase I with cancer. Arthritis Rheum 1992;35:724.
42. Kuwana M, Fujii T, Mimori T, et al. Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis: a report of two cases. Arthritis Rheum 1996;39:686-691.
43. Derk CT, Sakkas LI, Rasheed M, et al. Autoantibodies in patients with systemic sclerosis and cancer: a case-control study. J Rheumatol 2003;30:1994-1996.
44. Pontifex EK, Hill CL, Roberts-Thomson P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 2006 September 19; [epub ahead of print]. 2007;66:551-553.